TMC
FENC icon

Trellus Management Company’s Fennec Pharmaceuticals FENC Stock Holding History

Trellus Management Company’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,561
Closed -$93.3K – 59
2023
Q2 		$93.3K Sell
10,561
-1,300
-11% -$10.8K 0.12% 55
2023
Q1 		$98.7K Buy
+11,861
New +$110K 0.12% 49

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Trellus Management Company's FENC Position: Q3 2023 in Review

Trellus Management Company sold out of Fennec Pharmaceuticals (FENC) in Q3 2023, closing a stake of 10,561 shares — an estimated $93.3K sold.

Trellus Management Company first reported a position in FENC in Q1 2023 and held it in 2 quarters. The position peaked at $98.7K in Q1 2023. 55 funds tracked by Wall St. Rank hold FENC as of Q3 2023.

  • Trellus Management Company reported no remaining Fennec Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Trellus Management Company sold 10,561 Fennec Pharmaceuticals shares in Q3 2023, an estimated $93.3K.
  • Trellus Management Company first reported a position in Fennec Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Trellus Management Company's Fennec Pharmaceuticals position peaked at $98.7K in Q1 2023.
  • 55 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2023.

Based on Trellus Management Company's 13F filing for Q3 2023, filed 24 Oct 2023.